BMEA
Biomea Fusion, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.83
+2.23%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.79
From 52W high−31.46%
Volume1.63M
Market cap$132.65M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.79
From 52W high
−31.46%
Volume
1.63M
Market cap
$132.65M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.9x
P/E (TTM)
—
RSI (14)
58.0
MomentumView details →
1D Return
+2.23%
YTD Return
+44.35%
SummaryUpdated Jun 1, 2026
Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Redwood City, California. The company went public in April 2021 and focuses on developing innovative covalent small molecule drugs designed to treat patients with genetically defined cancers and metabolic diseases. Biomea Fusion represents part of the new generation of precision medicine companies that aim to target specific genetic mutations responsible for various diseases, particularly in oncology.
Similar companies
Latest newsMore news →
Biomea Fusion Inc completed enrollment for its Phase II diabetes trial, a milestone for its lead metabolic drug program.27d agoBiomea Fusion dosed the first patient in its OPAL study evaluating icovamenib in combination with semaglutide for obesity, assessing physical function, body weight, body composition, muscle health, and metabolic outcomes.38d ago